#Norway #Oslo #Bladder Cancer #Photocure #EAU 2026

Photocure's Commitment to Advancing Bladder Cancer Care at EAU 2026

In March 2026, the European Association of Urology (EAU) congress in London became a significant platform for Photocure ASA, recognized as the Bladder Cancer Company, to present vital advancements in bladder cancer care. This year’s event featured two notable “trial in progress” presentations that aim to revolutionize the diagnostic pathway for patients battling bladder cancer and enhance treatment outcomes through personalized care.

Focus on Innovation at EAU

The EAU annual congress is a pivotal event in the Uro-oncology calendar, recognized globally for showcasing the latest clinical and scientific advancements in urology. Photocure actively participated in this significant event with its innovative product, Hexvix®, which is designed to improve the detection and resection of bladder tumors. Notably, the company provided an educational opportunity for urologists who could not attend the congress, offering video interviews with presenters from the sessions, thus ensuring that critical findings reach a broader audience.

This initiative, supported by leading bladder cancer experts in Europe, Prof. M. Rouprêt from Sorbonne University and Prof. P. Gontero from the University of Torino, further underscores Photocure’s dedication to improving clinical practices through education and knowledge sharing.

Highlighted Trials at EAU 2026

One of the most intriguing presentations, titled “VI-RADS PDD-TURBT to Avoid Second-look and Resection (Re-TURBT) in Non-Muscle Invasive Bladder Cancers,” discusses the CUT-less trial. This innovative approach investigates whether second-look Transurethral Resection of Bladder Tumors (TURBT) can be omitted altogether by leveraging the accuracy of Magnetic Resonance Imaging (MRI) and enhanced cystoscopy using blue light. The CUT-less trial aims to tailor treatment strategies for patients with non-muscle invasive bladder cancer (NMIBC) and is designed to improve patient outcomes significantly.

The results from this trial, involving 327 patients across three years, hold the potential to inform new therapeutic pathways that are economically sustainable while continuing to prioritize patient welfare.

Another exciting trial introduced at the congress is “Evaluation of Urinary Minimal Residual Disease and Outcomes in High-Risk Non-Muscle Invasive Bladder Cancer,” utilizing UroAmp (developed by Convergent Genomics) to non-invasively assess bladder cancer presence. This study contrasts the effectiveness of standard white light and blue light cystoscopy in high-risk NMIBC patients, emphasizing the need for enhanced tumor margin visualization during surgeries. The findings from this trial could provide critical insights into treatment efficacy and long-term patient outcomes.

Advancing Personalized Care

Anders Neijber, Chief Medical Officer at Photocure, emphasized the company’s commitment to transforming uro-oncology through data-driven personalized care. He noted the increasing trend towards minimally invasive procedures and underlined how these trials aim to bridge existing data gaps within the care pathway. Neijber stated that personalized care is crucial for improving patients' clinical outcomes and enhancing overall healthcare value.

Photocure, in collaboration with medac, also hosted an event titled “Optimizing Care in Bladder Cancer,” engaging key clinicians to address current challenges in the management of bladder cancer. This collaboration reflects a shared commitment to enhancing evidence-based practices in bladder cancer care, focusing on improving patient pathways and outcomes, particularly for women.

The Broader Context of Bladder Cancer

Bladder cancer remains one of the most prevalent cancers globally, with high recurrence rates and substantial treatment costs. More than 220,000 deaths were reported in 2022 alone, with bladder cancer ranking fifth among cancers in men. With such a significant burden on patients and healthcare systems alike, innovative solutions and new treatment methodologies like those presented by Photocure are essential in addressing the pressing need for advancements in diagnosis and management.

The trials presented at EAU 2026 are not just clinical studies; they represent hope for a future where bladder cancer care is more effective, personalized, and patient-centered. As these studies unfold, they may lead the way to transformative changes in how bladder cancer is treated, ultimately improving the quality of life for those affected by this disease.

In conclusion, Photocure ASA's presentations at EAU 2026 mark a pivotal moment in the fight against bladder cancer, promising a shift towards more individualized, evidence-based treatment options that stand to benefit both patients and healthcare providers around the globe.